Efficacy and Safety of Secukinumab 150 mg with and Without Loading Regimen in Ankylosing Spondylitis: 104-week Results from MEASURE 4 Study

2018119 citationsJournal Articlegold Open Access

Authors

Novartis Pharma AG, Basel, Switzerland.

Good health and well-being

Published in: Rheumatology and Therapy

Volume 5, Issue 2, pp. 447-462

Field-Weighted Citation Impact: 11.53